Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: Motilal Oswal

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA | BSE: 524715 | ISIN: INE044A01036 | Industry: Pharmaceuticals
| Mid-range Performer

1656.0000 7.40 (0.45%)

NSE Sep 19, 2025 15:31 PM

Volume: 3.2M

Sun Pharmaceutical Industries Ltd.

22 May 2024, 12:00AM

1656.00

0.45%

The US and India businesses drive earnings growth

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharma (SUNP) reported a slight miss at the operational level for
4QFY24. This was due to lower-than-expected sales in the ROW market and
higher-than-expected opex for the quarter.

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

The Baseline | 19 Sep 2025

Market closes lower, JSW Energy arm to acquire Tidong Power

Trendlyne Marketwatch | 19 Sep 2025

Change is hard, and some Indian pharma companies are embracing it better than others

| 09 Aug 2022